159 related articles for article (PubMed ID: 17517052)
21. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients.
Wheeler CJ; Black KL; Liu G; Mazer M; Zhang XX; Pepkowitz S; Goldfinger D; Ng H; Irvin D; Yu JS
Cancer Res; 2008 Jul; 68(14):5955-64. PubMed ID: 18632651
[TBL] [Abstract][Full Text] [Related]
22. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
Trials; 2018 May; 19(1):293. PubMed ID: 29801515
[TBL] [Abstract][Full Text] [Related]
23. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme.
De Vleeschouwer S; Fieuws S; Rutkowski S; Van Calenbergh F; Van Loon J; Goffin J; Sciot R; Wilms G; Demaerel P; Warmuth-Metz M; Soerensen N; Wolff JE; Wagner S; Kaempgen E; Van Gool SW
Clin Cancer Res; 2008 May; 14(10):3098-104. PubMed ID: 18483377
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response.
Rüttinger D; van den Engel NK; Winter H; Schlemmer M; Pohla H; Grützner S; Wagner B; Schendel DJ; Fox BA; Jauch KW; Hatz RA
J Transl Med; 2007 Sep; 5():43. PubMed ID: 17868452
[TBL] [Abstract][Full Text] [Related]
25. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
[TBL] [Abstract][Full Text] [Related]
26. Autologous adoptive immune-cell therapy elicited a durable response with enhanced immune reaction signatures in patients with recurrent glioblastoma: An open label, phase I/IIa trial.
Lim J; Park Y; Ahn JW; Sim J; Kang SJ; Hwang S; Chun J; Choi H; Kim SH; Chun DH; Sung KS; Kwack K; Cho K
PLoS One; 2021; 16(3):e0247293. PubMed ID: 33690665
[TBL] [Abstract][Full Text] [Related]
27. Clinical trial of external beam-radiotherapy combined with daily administration of low-dose cisplatin for supratentorial glioblastoma multiforme--a pilot study.
Shinoda J; Sakai N; Hara A; Ueda T; Sakai H; Nakatani K
J Neurooncol; 1997 Oct; 35(1):73-80. PubMed ID: 9266443
[TBL] [Abstract][Full Text] [Related]
28. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.
Brown CE; Badie B; Barish ME; Weng L; Ostberg JR; Chang WC; Naranjo A; Starr R; Wagner J; Wright C; Zhai Y; Bading JR; Ressler JA; Portnow J; D'Apuzzo M; Forman SJ; Jensen MC
Clin Cancer Res; 2015 Sep; 21(18):4062-72. PubMed ID: 26059190
[TBL] [Abstract][Full Text] [Related]
29. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
Sampson JH; Heimberger AB; Archer GE; Aldape KD; Friedman AH; Friedman HS; Gilbert MR; Herndon JE; McLendon RE; Mitchell DA; Reardon DA; Sawaya R; Schmittling RJ; Shi W; Vredenburgh JJ; Bigner DD
J Clin Oncol; 2010 Nov; 28(31):4722-9. PubMed ID: 20921459
[TBL] [Abstract][Full Text] [Related]
30. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma.
Phuphanich S; Wheeler CJ; Rudnick JD; Mazer M; Wang H; Nuño MA; Richardson JE; Fan X; Ji J; Chu RM; Bender JG; Hawkins ES; Patil CG; Black KL; Yu JS
Cancer Immunol Immunother; 2013 Jan; 62(1):125-35. PubMed ID: 22847020
[TBL] [Abstract][Full Text] [Related]
31. P53-negative status and gross total resection as predictive factors for autologous tumor vaccine treatment in newly diagnosed glioblastoma patients.
Yamada E; Ishikawa E; Miyazaki T; Miki S; Sugii N; Kohzuki H; Tsurubuchi T; Sakamoto N; Watanabe S; Matsuda M
Neurooncol Adv; 2023; 5(1):vdad079. PubMed ID: 37484760
[TBL] [Abstract][Full Text] [Related]
32. Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial.
Yao Y; Luo F; Tang C; Chen D; Qin Z; Hua W; Xu M; Zhong P; Yu S; Chen D; Ding X; Zhang Y; Zheng X; Yang J; Qian J; Deng Y; Hoon DSB; Hu J; Chu Y; Zhou L
Cancer Immunol Immunother; 2018 Nov; 67(11):1777-1788. PubMed ID: 30159779
[TBL] [Abstract][Full Text] [Related]
33. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma.
Hayes RL; Koslow M; Hiesiger EM; Hymes KB; Hochster HS; Moore EJ; Pierz DM; Chen DK; Budzilovich GN; Ransohoff J
Cancer; 1995 Sep; 76(5):840-52. PubMed ID: 8625188
[TBL] [Abstract][Full Text] [Related]
34. Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial.
Ardon H; Van Gool SW; Verschuere T; Maes W; Fieuws S; Sciot R; Wilms G; Demaerel P; Goffin J; Van Calenbergh F; Menten J; Clement P; Debiec-Rychter M; De Vleeschouwer S
Cancer Immunol Immunother; 2012 Nov; 61(11):2033-44. PubMed ID: 22527250
[TBL] [Abstract][Full Text] [Related]
35. Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma.
Schuessler A; Smith C; Beagley L; Boyle GM; Rehan S; Matthews K; Jones L; Crough T; Dasari V; Klein K; Smalley A; Alexander H; Walker DG; Khanna R
Cancer Res; 2014 Jul; 74(13):3466-76. PubMed ID: 24795429
[TBL] [Abstract][Full Text] [Related]
36. Predictive value of diffusion MRI-based parametric response mapping for prognosis and treatment response in glioblastoma.
Rydelius A; Bengzon J; Engelholm S; Kinhult S; Englund E; Nilsson M; Lätt J; Lampinen B; Sundgren PC
Magn Reson Imaging; 2023 Dec; 104():88-96. PubMed ID: 37734574
[TBL] [Abstract][Full Text] [Related]
37. Long-term survivor of relapsed MFH on the thigh treated with autologous formalin-fixed tumor vaccine (AFTV) combined with limb-sparing surgery and radiotherapy.
Todoroki T; Kondo T; Sugahara S; Morishita Y; Mori K; Ohno T
World J Surg Oncol; 2011 Aug; 9():96. PubMed ID: 21864347
[TBL] [Abstract][Full Text] [Related]
38. Low-dose fractionated radiotherapy and concomitant chemotherapy for recurrent or progressive glioblastoma: final report of a pilot study.
Balducci M; Diletto B; Chiesa S; D'Agostino GR; Gambacorta MA; Ferro M; Colosimo C; Maira G; Anile C; Valentini V
Strahlenther Onkol; 2014 Apr; 190(4):370-6. PubMed ID: 24429479
[TBL] [Abstract][Full Text] [Related]
39. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial.
Bloch O; Crane CA; Fuks Y; Kaur R; Aghi MK; Berger MS; Butowski NA; Chang SM; Clarke JL; McDermott MW; Prados MD; Sloan AE; Bruce JN; Parsa AT
Neuro Oncol; 2014 Jan; 16(2):274-9. PubMed ID: 24335700
[TBL] [Abstract][Full Text] [Related]
40. Primary glioblastoma multiforme in younger patients: a single-institution experience.
Ulutin C; Fayda M; Aksu G; Cetinayak O; Kuzhan O; Ors F; Beyzadeoglu M
Tumori; 2006; 92(5):407-11. PubMed ID: 17168433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
